Investment Rating - The report maintains a "Buy" rating for the medical services industry [5][66]. Core Insights - The medical and biological sector experienced a decline of 2.06% this week, ranking 28th among 31 primary industries [1][11]. - The AI pharmaceutical company Insilico Medicine was listed on the Hong Kong Stock Exchange, raising HKD 2.277 billion, marking it as the highest fundraising biotech IPO in 2025 [4][63]. - AI technology is significantly reducing the time and costs associated with drug discovery and clinical trials, with potential savings of approximately USD 26 billion annually in compound screening and clinical trial costs [5][65]. Summary by Sections Industry Performance - The medical services sector's PE (ttm) is 31.28X, with a PB (lf) of 3.17X, showing a decrease of 0.52X in PE and 0.05X in PB from the previous week [3][30]. - The medical services II sub-industry index closed at 6363.18 points, down 1.40% [22][23]. Company Performance - Top-performing companies in the medical services sector include: - Purui Eye Hospital (+5.3%) - Sanbo Brain Science (+4.7%) - Puris (+3.0%) - Tigermed (+2.9%) - Baicheng Pharmaceutical (+2.2%) - Underperforming companies include: - Bid Pharmaceutical (-6.6%) - Sunshine Nuohua (-6.1%) - Zhaoyan New Drug (-5.2%) - International Medicine (-4.0%) - Kanglong Chemical (-3.5%) [2][28]. Investment Recommendations - The report suggests focusing on high-growth areas such as ADC CDMO and peptide CDMO in the pharmaceutical outsourcing services, with companies like WuXi AppTec, Haoyuan Pharmaceutical, and WuXi Biologics being highlighted [9][66]. - It also recommends looking at third-party medical testing laboratories and consumer healthcare sectors, particularly in ophthalmology and dentistry, with companies like Aier Eye Hospital and Dean Diagnostics [9][66].

AI正将一门依赖试错的实验科学，转变为一门可预测、可编程的数据科学。 作者 | 申思琦 编辑 | 硬 AI "未来，所有的生物学都将以'计算机模拟'（in silico）为起点，并以'计算机模拟'为很大程度的终点。"（Almost everything will largely start in silico, largely end in silico） 当英伟达（NVIDIA）创始人兼CEO黄仁勋在J.P. Morgan医疗健康大会和GTC大会的聚光灯下反复提及这一论断时，生物学正在从一门依赖试错的实验科学，转变 为一门可预测、可编程的数据科学。 而英矽智能（Insilico），正是这个被黄仁勋多次 点名 的"第一性原理"践行者。 2025年12月30日，英矽智能（3696.HK）在香港联合交易所主板正式挂牌， 开盘价报35港元，较发行价升45%，市值达到195亿港元 。 | 10 901 日 周 月 8 年 1分 5分 15分 30分 60分 8 80期 10图 | 角 九期 酮自选 ▼ 0007200 | | 英矽智能-B 03696 | | 60 95 | 35.000 9567 | 38.347 ...

当英伟达（NVIDIA）创始人兼CEO黄仁勋在J.P. Morgan医疗健康大会和GTC大会的聚光灯下反复提及这一论断时，生物学正在从一门依赖试错的 实验科学，转变为一门可预测、可编程的数据科学。 而英矽智能（Insilico），正是这个被黄仁勋多次点名的"第一性原理"践行者。 "未来，所有的生物学都将以'计算机模拟'（in silico）为起点，并以'计算机模拟'为很大程度的终点。"（Almost everything will largely start in silico, largely end in silico） 2025年12月30日，英矽智能（3696.HK）在香港联合交易所主板正式挂牌，开盘价报35港元，较发行价升45%，市值达到195亿港元。 | ■ 分时 日 周 月 季 年 1分 5分 15分 30分 60分 多 周 周 安 安 | 竟 九转 则自选 ▼ | | 英矽智能-B 03696 | | 最新 | 35.000 均价 | 38.347 | | --- | --- | --- | --- | --- | --- | --- | --- | | 年67回服-B 分析 15H1: 38 ...

Core Viewpoint - InSilico Medicine is pursuing an IPO in Hong Kong after multiple failed attempts, with a significant accumulated loss of $591 million from 2021 to 2024, raising concerns about its long-term viability and business model [1][4][5]. Financial Performance - The company reported revenues of $4.713 million, $30.147 million, $51.18 million, and $85.834 million from 2021 to 2024, respectively, with net losses of $131 million, $222 million, $212 million, and $17.096 million during the same period [5][6]. - The projected revenue for 2024 shows a growth of 92% compared to 2022, with a significant reduction in net loss by 92% [6][7]. Business Model and Operations - InSilico Medicine's core business model focuses on AI-driven drug discovery and pipeline drug development, with 92.9% of its 2024 revenue coming from this segment [7][8]. - The company has 15 candidate drugs in its pipeline, primarily in fibrosis, oncology, and immunology, but has yet to achieve commercialization [7][8]. Funding and Future Plans - The IPO proceeds are intended for further clinical development of key drug candidates, development of new AI models, and operational funding [4][5]. - The company completed a $100 million Series E financing round, increasing its valuation from $894.7 million to $1.3305 billion, reflecting a 48.71% increase over two and a half years [8].